Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis

Citation
Curie, Aurore, Kathy Yang, Irving Kirsch, Randy L. Gollub, Vincent des Portes, Ted J. Kaptchuk, and Karin B. Jensen. 2015. “Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis.” PLoS ONE 10 (7): e0133316. doi:10.1371/journal.pone.0133316. http://dx.doi.org/10.1371/journal.pone.0133316.

Published Version
doi:10.1371/journal.pone.0133316

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:21462545

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
RESEARCH ARTICLE

Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis

Aurore Curie1,2,3,4,5*, Kathy Yang1, Irving Kirsch6,7, Randy L. Gollub1, Vincent des Portes2,3,4, Ted J. Kaptchuk6, Karin B. Jensen1,6,8

1 Department of Psychiatry, Massachusetts General Hospital/Harvard Medical School, Martinos Center for Biomedical Imaging, Boston, Massachusetts, United States of America, 2 L2C2, Institut des Sciences Cognitives, CNRS UMR5304, Bron, France, 3 Centre de Référence Déficience Intellectuelles de Causes Rares, Hôpital Femmes Mères Enfants, Hospices Civils de Lyon, Bron, France, 4 Université Claude Bernard Lyon1, Lyon, France, 5 EPICIME-CIC1407/INSERM, Bron, France, 6 Program in Placebo Studies, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, Massachusetts, United States of America, 7 School of Psychology, Plymouth University, Plymouth, United Kingdom, 8 Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden

* aurorecurie@yahoo.fr

Abstract

Background
Genetically determined Intellectual Disability (ID) is an intractable condition that involves severe impairment of mental abilities such as learning, reasoning and predicting the future. As of today, little is known about the placebo response in patients with ID.

Objective
To determine if placebo response exists in patients with genetically determined ID.

Data sources and Study selection
We searched Medline/PubMed, EMBASE, CENTRAL and PsycINFO to find all placebo-controlled double-blind randomized clinical trials (RCTs) in patients with genetically determined ID, published up to April 2013, focusing on core ID symptoms.

Data extraction and synthesis
Two investigators extracted outcome data independently.

Main outcomes and measures
Bias-corrected standardized mean difference (Hedge’s g) was computed for each outcome measure, using the Comprehensive Meta-Analysis software. A priori defined patient subgroups were analyzed using a mixed-effect model. The relationship between pre-defined continuous variable moderators (age, IQ, year of publication and trial duration) and effect size was analyzed using meta-regression.
Results
Twenty-two placebo-controlled double-blind RCTs met the inclusion criteria (n = 721, mean age = 17.1 years, 62% men, mean trial duration = 35 weeks). There was a significant overall placebo response from pre- to post-treatment in patients with ID (g = 0.468, p = 0.002), both for “subjective outcomes” (a third-person’s evaluation of the patient) (g = 0.563, p = 0.022) and “objective outcomes” (direct evaluation of the patient’s abilities) (g = 0.434, p = 0.036). Individuals with higher IQ had higher response to placebo (p = 0.02) and no placebo response was observed in ID patients with comorbid dementia. A significant effect of age (p = 0.02) was found, indicating higher placebo responses in treatment of younger patients.

Conclusions and relevance
Results suggest that patients with genetically determined ID improve in the placebo arm of RCTs. Several mechanisms may contribute to placebo effects in ID, including expectancy, implicit learning and “placebo-by-proxy” induced by clinicians/family members. As the condition is refractory, there is little risk that improvements are explained by spontaneous remission. While new avenues for treatment of genetically determined ID are emerging, our results demonstrate how contextual factors can affect clinical outcomes and emphasize the importance of being vigilant on the role of placebos when testing novel treatments in ID.

Introduction
Intellectual Disability (ID) is characterized by deficits in intellectual functions, such as reasoning, abstract thinking, judgment and learning from experience. The defining features of ID are confirmed by clinical assessment and standardized intelligence testing (overall Intelligence Quotient (IQ) <70), combined with deficits in adaptive functioning that result in failure to meet developmental and sociocultural standards, manifested during the developmental period (DSM-V) [1]. Genetic causes of ID include visible chromosomal anomalies (such as Down’s syndrome, which is the most frequent aneuploidy), chromosomal microdeletion (including Prader-Willi and Williams’ syndrome) and monogenic diseases (such as mutation of the gene FMR1 leading to Fragile X syndrome). None of these disorders improve spontaneously over time. If anything, patients with Down’s syndrome risk an age-related cognitive decline after 40, which progresses to Alzheimer’s-like dementia [2]. Until recently, treatment for ID focused mainly on symptom management (including attention deficits and anxiety), and on minimizing the complications related to comorbidities (like epilepsy). New pharmacological treatment options, that target the underlying defect related to each genetic mutation, are currently being explored and may offer opportunities to directly improve cognition [3]. In spite of the emerging interest in cognitive improvement in ID, little is known about patients’ ability to improve core ID symptoms as a response to placebo treatment. We decided to examine to what extent placebo treatment in randomised controlled trials (RCTs) led to clinical improvement in patients with ID. As current theories suggest that placebo effects depend on cognitive inferences based on prior experience (learning) or treatment expectations (reasoning) [4], the severe cognitive deficits in ID may challenge existing placebo models.

In clinical trials, placebo effects can be substantial and are often attributed to the expectations formed at the beginning of the trial, as studies show that the information content may shape placebo outcomes [5]. Yet, little is known about the placebo response in individuals with
limited ability to understand the significance of participating in a clinical trial. This is noteworthy, as the investigation of placebo responses in patients with ID may (i) elucidate the impact of the “provision of care” independent of active medication [6], (ii) revise accepted theories of placebo mechanisms that focus on learning and higher order cognition [4, 7, 8], and (iii) improve the way clinical trials are performed and interpreted [9].

The brain mechanisms associated with placebo responses have been described in studies of Parkinson disease [10, 11], pain [12–15], depression [16] and anxiety [17, 18] and suggest a model of prefrontal cognitive control that modulates activity and neurotransmitter function further down the neural axis. Even if subcortical structures [11, 17, 19], and even spinal structures [20, 21], have been associated with placebo responses, the role of executive brain function is considered critical for processing the treatment expectations that create placebo responses. However, recent evidence from our group suggest that human placebo mechanisms can operate outside of conscious awareness [22, 23], challenging the role of higher-order cognitions and calling for closer investigation and refinement of the role of intellectual capacity in theories of placebos.

Here, we used data from RCTs focusing on core ID symptoms (behavioral or cognitive developmental functions) to investigate if patients with genetically determined ID display placebo responses. To address the critical question of report bias, we compared the placebo response to subjective (a third person’s evaluation of the patient, e.g., clinicians’ or parents’ ratings) with more objective outcome measures (direct evaluation of the patient’s abilities, e.g., motor or memory task). By limiting our investigation to genetically determined syndromes we controlled for the possibility that acquired ID (e.g. from childhood disease) could be an advantage due normal brain development before ID onset. There is always a possibility that the placebo response is partially represented by spontaneous remission, or the natural history of the condition being treated. Yet, genetically determined ID is a refractory condition [2], with little likelihood of improvement due to spontaneous remission, rather than an effect of the treatment intervention. Thanks to progress in molecular genetics, and a better knowledge about the physiopathology of each disease, new avenues are emerging for treatment of genetically determined ID, adding to the importance of understanding the placebo response in ID clinical trials.

Methods

Data source

We adhered to the PRISMA guidelines for reporting meta-analyses (www.prisma-statement.org). We searched Medline/PubMed, EMBASE, CENTRAL and PsycINFO and restricted our search to randomized placebo-controlled trials in patients with genetically determined ID from one of the following diagnoses: Fragile X (FX), Down’s (DS), Prader-Willi’s (PW), and Williams’ syndromes. The search terms ‘Randomized controlled trial’, ‘Clinical Trial’, ‘Therapeutics’ AND ‘Fragile X syndrome’, ‘Down’s syndrome’, ‘Prader-Willi’s syndrome’, ‘Williams syndrome’ were used. All studies published before April 2013 were considered for inclusion.

Study selection

The criteria for inclusion were randomized double-blind placebo-controlled trials in patients with one of the a priori defined genetically determined syndromes of ID, of any age. Studies were excluded if (i) outcomes were not evaluation of behavioral or cognitive-developmental functions (e.g. outcomes such as weight, height), (ii) if the treatment targeted a peripheral comorbidity to intellectual disability (e.g. bone mass, acute lymphoblastic leukemia, supra-gingival plaque accumulation). The selection of studies followed the Consolidated Standards Of
Data extraction and quality assessment

Eligibility judgment of studies was performed in consensus meeting before extraction of data. Studies were excluded if (i) the studies did not report any inference test or enough descriptive information to compute an effect size (for instance, percentages or means and a variability measure), (ii) less than five patients were included, (iii) no separate reports for drug/placebo were available, (iv) not a randomized trial (placebo group added from previous study), (v) only healthy controls were treated and no patients. All data was extracted independently by two separate reviewers (KY, KJ). Once all data was extracted, the values were compared and inconsistencies were resolved in consensus meetings and confirmed with a third reviewer (AC).

For each study, we extracted outcome data for the placebo and drug treatment arms separately, both at baseline and at study end. Each outcome was categorized as either an objective (direct measurement of the patient’s abilities, e.g. a motor or memory task) or subjective measure (a third person’s evaluation of the patient, e.g. a clinician’s rating of symptom severity). Moreover, each outcome was classified according to one of seven mental processes, or domains: attention/executive function, language, memory, cognitive-developmental level, autistic traits, abnormal behavior, and Global Improvement. Measured characteristics of participants included diagnosis, physical age, IQ-level, proportion of men and women and presence of comorbid dementia. Design characteristics included design type, intervention drug(s), country of study origin, treatment duration, number of treatment intakes daily, and year of publication.

Data synthesis and analysis

Data management, and calculation of bias-corrected standardized mean difference (Hedges’s g) were performed using the Comprehensive Meta-Analysis software version 3.0 (www.meta-analysis.com).

Since considerable heterogeneity was expected, all analyses were performed with random-effects rather than a fixed-effects model [24]. The reported Q statistic reflects the distance of each study from the mean effect (weighted, squared, and summed overall studies). Additional sensitivity analyses explored the effect of bias on the results. First, we assessed the presence of publication bias visually by Funnel plot and formally by its statistical analogues, the Begg and Mazumdar-rank correlation test. Sensitivity to the estimate of publication bias was assessed by the Trim and Fill method.

Two types of analyses for placebo and drug effects were performed: one assessing the effect size of pre-post treatment within each treatment arm (drug and placebo separately), the other assessing the effect size between drug and placebo within each study. When a study provided several outcome measures, all of them were combined to provide one value per study.

A priori defined subgroups of data were analyzed by mixed-effects analyses, using the weighted mean effect size for each group (based on random-effect weights), to test the difference between these values (Q statistic). The subgroups were: patients with co-morbid dementia/patients with no dementia, subjective/objective outcomes, type of diagnosis (FX, DS, PW) and drug category (Ampakine, anorexid drug, GABA agonist, Growth Hormone, Inhibitor of acetylcholine esterase, NMDA antagonist, tetracycline, thyroxine, aminoacid, vitamins).

The relationship between pre-defined continuous variable moderators (age, IQ, year of publication and trial duration) and effect size was analyzed using meta-regression, as implemented in the Comprehensive Meta-Analysis software.
Results

Description of studies
The total number of studies that met the inclusion criteria and were included in the final analyses were \( k = 22 \) (DS \( k = 14 \); FX \( k = 6 \); PW \( k = 2 \); Williams syndrome \( k = 0 \)), comprising 721 patients in the placebo arm. Fig 1 shows the trial flow and Table 1 provides descriptive features of the studies. The mean duration of studies was 35 weeks (SD 37, range 4–156 weeks). 62% of the participants were male, and the mean age in the placebo arm was 17.1 (SD 15.6, range 0–55) and 17.8 (SD 16, range 0–53) in the drug arm. Studies were conducted in North America (\( k = 13 \)), Europe (\( k = 6 \)), Asia (\( k = 2 \)), and Australia (\( k = 1 \)).

Placebo and drug response
The pre-post comparison of treatment outcomes in the placebo arm of the included trials showed a significant overall placebo response, based on study effect size (\( g = 0.468, SE = 0.150, p = 0.002 \), see Fig 2). We identified significant heterogeneity across studies (\( Q = 201.9, df = 21, p < 0.001, I^2 = 89.59, \tau^2 = 0.41 \)), and attempted to explain this variability by means of subgroup analyses. The same analysis was performed for the drug arm, where a pre-post comparison showed a significant drug response (\( g = 0.678, SE = 0.171, p = 0.0001 \)). A within-study comparison of drug and placebo (traditional drug-placebo meta-analysis) showed a non-significant difference (\( g = 0.061, SE = 0.052, p = 0.24 \)). For both treatment arms, the Funnel plots revealed no evident publication bias. The Begg’s test result was not statistically significant and the Trim and Fill method did not lead to any adjustment of the results for the placebo arm. As there were three studies with clearly higher effect size than the rest ([38, 40, 45]), we tested if the placebo meta-analysis would still be significant with them removed. A random effects analysis (\( k = 19 \)) revealed a significant yet smaller effect size (\( g = 0.2, SE = 0.071, p = 0.01 \)) compared to overall effect size when including all studies (\( g = 0.468 \)).

Comparison of subjective and objective outcomes
We compared the placebo response to subjective measures (a third person’s evaluation of the patient, e.g., clinicians or parents’ ratings of severity) with more objective outcome measures.

![Fig 1. Trial flow chart.](https://example.com/fig1.png)

doi:10.1371/journal.pone.0133316.g001
(direct evaluation of the patient’s abilities such as motor or memory task) in order to address the question of report bias when responding to placebo treatment. We found significant placebo responses both for subjective ($g = 0.563, \ SE = 0.246, \ p = 0.022$) and objective ($g = 0.434, \ SE = 0.207, \ p = 0.036$) outcomes. A comparison between objective and subjective outcomes was non-significant ($Q = 0.161, \ df = 1, \ p = 0.688$), indicating that placebo responses are not significantly greater for subjective outcomes than for objective measures.

Table 1. Study characteristics. Descriptive features of the studies included in the placebo controlled trials of the meta-analysis.

| Study name            | Diagn. | Placebo arm No. of patients N | Age Mean | Age SD | Drug arm No. of patients N | Age Mean | Age SD | Male (%) | Study design | Type of drug | Trial duration (weeks) |
|-----------------------|--------|--------------------------------|----------|--------|---------------------------|----------|--------|----------|--------------|--------------|------------------------|
| Bennett, 1983 [25]    | DS     | 10                             | 10       | 3      | 10                        | 11       | 2      | 50       | Parallel     | Vitamins**    | 35                     |
| Berry-Kravis, 2006 [26] | FX   | 25                             | 25       | 8      | 24                        | 31       | 10     | 78       | Parallel     | Ampakine      | 4                      |
| Berry-Kravis, 2012 [27] | FX   | 56                             | 16       | *      | 56                        | 16       | *      | 87       | Crossover    | GABA-Agonist | 4                      |
| Blehaut, 2010 [28]    | DS     | 44                             | 1        | 1      | 43                        | 1        | 1      | 53       | Parallel     | Vitamins**    | 52                     |
| Boada, 2012 [29]      | DS     | 19                             | 23       | 4      | 18                        | 23       | 4      | 37       | Parallel     | NMDA-antag.  | 16                     |
| Ellis, 2008 [30]      | DS     | 33                             | 0        | 0      | 106                       | 0        | 0      | 57       | Parallel     | Vitamins**    | 78                     |
| Hagerman, 1986 [31]   | FX     | 25                             | 16       | 10     | 25                        | 16       | 10     | 100      | Crossover    | Vitamins**    | 26                     |
| Hanney, 2012 [32]     | DS     | 74                             | 51       | 7      | 72                        | 52       | 7      | 57       | Parallel     | NMDA-antag.  | 52                     |
| Haqq, 2003 [33]       | PW     | 12                             | 9        | 3      | 12                        | 9        | 3      | 50       | Crossover    | Growth hormone | 26                     |
| Johnson, 2003 [34]    | DS     | 9                              | 25       | 8      | 9                         | 30       | 10     | 58       | Parallel     | AChEI         | 12                     |
| Kishnani, 2009 [35]   | DS     | 59                             | 26       | 6      | 56                        | 24       | 5      | 63       | Parallel     | AChEI         | 12                     |
| Kishnani, 2010 [36]   | DS     | 65                             | 13       | 2      | 62                        | 13       | 2      | 52       | Parallel     | AChEI         | 10                     |
| Kondoh, 2011 [37]     | DS     | 10                             | 44       | *      | 11                        | 47       | *      | 0        | Parallel     | AChEI         | 24                     |
| Leigh, 2013 [38]      | FX     | 53                             | 9        | 4      | 50                        | 9        | 4      | 85       | Crossover    | Tetracycline  | 13                     |
| Prasher, 2002 [39]    | DS     | 13                             | 55       | 5      | 14                        | 53       | 8      | 50       | Parallel     | AChEI         | 24                     |
| Pueschel, 1980 [40]   | DS     | 20                             | 0        | 0      | 69                        | 0        | 0      | 56       | Parallel     | Vitamins**    | 156                    |
| Sahu, 2013 [41]       | FX     | 10                             | 8        | 3      | 10                        | 10       | 3      | 100      | Parallel     | AChEI         | 12                     |
| Selikowitz, 1990 [42] | PW     | 15                             | 14       | *      | 15                        | 14       | *      | [30]     | Crossover    | Anorexic      | 6                      |
| Smith, 1984 [43]      | DS     | 28                             | 11       | 3      | 28                        | 11       | 3      | 71       | Parallel     | Vitamins**    | 35                     |
| Torrioli, 2008 [44]   | FX     | 27                             | 9.18     | *      | 24                        | 9.18     | *      | 100      | Parallel     | L-acetyl carnitine | 52                     |
| van Trottenburg, 2005 [45] | DS  | 91                             | 0        | 0      | 90                        | 0        | 0      | 55       | Parallel     | Thyroxine     | 104                    |
| Weathers, 1983 [46]   | DS     | 23                             | 12       | *      | 24                        | 12       | *      | 66       | Parallel     | Vitamins**    | 17                     |
| Placebo controlled studies |   | 721                           | 17.1     | 15.6   | 828                       | 17.8     | 16     | 62       | 35                      |

* not provided

** We used “vitamins” as a category for studies using either folic acid alone or a combination of vitamins, minerals and/or antioxidants.

Abbreviations: Down Syndrome (DS), Fragile X Syndrome (FX) and Prader-Willi Syndrome (PW). Gamma-Aminobutyric acid (GABA) agonist, N-metyl-D-aspartat (NMDA) antagonist, Acetylcholinesterase Inhibitor (AchEI).

doi:10.1371/journal.pone.0133316.t001
Effect of mental processes categories

The effect size of the placebo response differed significantly by different mental process categories ($Q = 13.288$, df = 6, $p = 0.039$). Table 2 shows the results observed for each category. The pre-post comparison for autistic traits, abnormal behavior, cognitive and developmental skills and Clinical Global Improvement showed a significant placebo response. However, no significant placebo response was observed on attention, language and memory. The drug response also differed significantly by mental process categories ($Q = 17.348$, df = 6, $p = 0.008$). No significant category difference was seen between drug and placebo.

### Table 2. Placebo and drug responses by mental process categories.

The total number of scales used for assessment of treatment outcomes were grouped into 7 different mental process categories, or domains. Four out of seven domains had a significant placebo response and five out of seven domains had a significant drug response. Clinical Global Impression (CGI) assessments are commonly used as study endpoints in clinical trials. Here, CGI is represented by one category, even if it is not a mental process.

| Mental process                  | Placebo response | Drug response | Drug / Placebo comparison |
|---------------------------------|------------------|---------------|---------------------------|
|                                 | $g$ SE p-value    | $g$ SE p-value| $Q$ df(Q) p-value         |
| Attention ($k = 2$)             | 0.056 0.229 0.81 | 0.180 0.234 0.441 | 0.143 1 0.71              |
| Language ($k = 8$)              | 0.017 0.064 0.79 | 0.121 0.063 0.05* | 1.327 1 0.25              |
| Memory ($k = 4$)                | 0.174 0.132 0.19 | 0.282 0.159 0.08  | 0.272 1 0.60              |
| Cognitive and developmental ($k = 17$) | 0.305 0.121 0.01* | 0.521 0.137 0.0001**** | 1.394 1 0.24              |
| Abnormal Behavior ($k = 7$)     | 0.278 0.09 0.002*** | 0.480 0.127 0.0001**** | 1.686 1 0.19              |
| Autistic traits ($k = 3$)       | 0.336 0.161 0.037* | 0.394 0.142 0.006** | 0.073 1 0.79              |
| CGI ($k = 3$)                   | 2.215 1.049 0.035* | 2.004 0.800 0.01* | 0.026 1 0.87              |

* < .05
** < .01
*** < .005
**** < .001
Effect of Intelligence level (IQ) on treatment outcomes

Using a regression model, we assessed the effect of IQ (which varied from 20 up to 65) on treatment response and found a significant effect of IQ corrected for age on placebo responses ($Q = 7.48, df = 2, p = 0.02$), represented by larger placebo responses in patients with higher IQ. There was no similar effect for drug response ($Q = 0.46, df = 2, p = 0.80$).

Effect of age on treatment outcomes

There was a significant effect of age on placebo effect size ($Q = 5.25, df = 1, p = 0.02$), indicating that younger patients had larger placebo responses (Fig 3). We found a comparable effect of age on drug effect size ($Q = 8.56, df = 1, p = 0.0034$).

Effect of dementia on treatment outcomes

Comorbid dementia in patients with ID had a significant effect on placebo responses ($Q = 4.249, df = 1, p = 0.039$), but not on drug responses ($Q = 1.961, df = 1, p = 0.161$). Specifically, patients with no dementia showed robust placebo responses ($g = 0.508, SE = 0.160, p = 0.002$) whereas patients with comorbid dementia had virtually no response to placebo ($g = -0.050, SE = 0.218, p = 0.82$).

Regression with trial duration

We found a positive effect of trial duration on placebo effect size ($Q = 16.38, df = 1, p = 0.0001$), with results pointing to larger effect sizes with longer trial durations. Two outliers appeared to drive the effect [40, 45] and with them removed the effect of trial duration was non-significant. Nonetheless, removal of these outliers did not affect the observation that the placebo response did not diminish over time. This finding is contrary to the common belief that placebo responses would be short lasting and wane with time [49].

Fig 3. Effect of age on placebo effect size. There was a significant effect of age on placebo effect size ($g$), represented by higher placebo responses in the youngest patients included in this meta-analysis ($p < .05$). It is possible that the results are explained by stronger placebo-by-proxy effects in young children, as parents and caregivers express high encouragement, attention and support to babies. The intensive care and attention given to young children may wane over time and thus lessen the placebo effects in older ID patients.

doi:10.1371/journal.pone.0133316.g003
Effect of diagnosis category

The effect size of the placebo response differed significantly between diagnostic categories ($Q = 7.367, df = 2, p = 0.025$). Placebo responses were observed both in DS ($g = 0.510, SE = 0.198, p = 0.01$) and FX ($g = 0.590, SE = 0.273, p = 0.03$), but not in PW patients ($g = -0.154, SE = 0.199, p = 0.44$). The number of studies included in the PW group was likely too small ($k = 2$) to allow enough statistical power to this analysis. Conversely, the effect size of the drug response did not significantly differ by diagnosis category ($Q = 3.722, df = 2, p = 0.16$).

Regression with year of publication

The possible effects of time on the development of drugs with high efficacy, and the associated increase in treatment expectations conveyed to patients and their families, was assessed by a regression of treatment effect size and publication year, ranging from 1980 to 2013. We did not find any effect of the year of publication and effect size, neither in placebo ($Q = 0.06, df = 1, p = 0.81$), nor drug ($Q = 1.34, df = 1, p = 0.25$).

Effect of drug category

A regression model revealed that the effect size of both placebo and drug responses differed significantly by drug category (placebo $Q = 158.243, df = 9, p = 0.0001$ and drug $Q = 144.433, df = 9, p = 0.0001$ respectively). Unpacking the overall regression model shows that trials involving either a GABA agonist, Inhibitor of acetylcholine esterase, tetracycline, thyroxine, L-acetyl carnitine or vitamins had a significant drug response. Among them, the trials involving an inhibitor of acetylcholine esterase did not show a comparable placebo response, possibly related to the presence of patients with comorbid dementia in these studies.

Discussion

To our knowledge, this meta-analysis presents the first account of placebo responses in ID patients and the first evaluation of the role of IQ in placebo mechanisms. Here, we demonstrate that patients with ID display significant placebo responses in spite of severe impairment of mental abilities such as learning, reasoning, abstract thinking and predicting the future. The overall effect size of placebo responses in this study ($g = 0.5$) is considered a “medium” effect and is comparable to the placebo response in adult patients without ID [47, 48] and in children [50] across a range of domains such as migraine, depression, Attention Deficit Hyperactivity Disorder and osteoarthritis. Previous meta-analyses have used the same approach to studying placebo responses in different clinical populations, using data from the placebo arm of RCTs in e.g. depression [51], irritable bowel syndrome [52], restless legs [53], and schizophrenia [54]. The strong evidence for placebo responses in ID, illustrated both in subjective and more objective outcomes, and in a wide range of behavioral and cognitive domains, challenges current theories of placebo mechanisms and suggests possibilities for change in the delivery of care. The fact that there was no significant difference in placebo effect size between subjective and objective outcome measures suggests that placebo responses in ID is not an effect of report bias, but likely represents a true improvement of patients’ symptoms. Conversely, if placebo effects had mainly been present in response to subjective reports (given by caretakers with no intellectual deficiency) one could not have concluded that individuals with ID display placebo responses. Given the refractory nature of genetically determined ID, it seems reasonable to assume that the improvements in response to placebos are primarily related to the provision and context of care, and not to natural remission of ID symptoms. This suggests that a supportive and attentive environment may lead to improvements in patients with ID.
The traditional drug versus placebo meta-analysis did not reveal any significant difference between drug and placebo. It is interesting to note that, we found a significant drug response from baseline in the drug arm. It is likely that this drug effect, which reflects both drug effect per se and placebo responses, is primarily related to placebo responses we observed in these studies.

Possible mechanisms of placebo responses in ID

This meta-analysis only included genetically determined ID, i.e. a condition that existed from conception, thus ensuring that the observed placebo response was not confounded by patients with a normal brain development before onset of ID. One key mechanism of placebo responses, described in individuals without ID, involves conscious expectancy [55]. The content of information related to treatment, such as referring to a topical placebo cream as "inert and with no effect" or as a "powerful painkiller" [56], can manipulate expectation and mediate placebo effects. Yet, it seems unlikely that the explicit information content play a major role in generating placebo responses in patients with ID, given their specific reasoning and language difficulties (both in comprehension and production).

Placebo effects can also be induced by mechanisms that are automatic and operate on a non-conscious level, such as associative learning (conditioning) [57]. Placebo responses have also been demonstrated in treatment of animals [58, 59]. In a previous study we challenged the exclusive role of conscious cognitions in human placebo responses and suggest that treatment cues may be implicitly embedded in the patient–clinician interaction and clinical environment [22, 23]. It is likely that non-conscious placebo mechanisms may play a role in patients with ID, as they involve learning that does not rely on abstraction.

Closely related to non-conscious placebo effects, and a third possible mechanism, is the implicit social influence of "placebo by proxy" [60], which has been mentioned apropos of placebo effects in young children. Placebo by proxy can operate in two ways. It might produce a genuine change in the patient’s condition, and/or it might alter the parent or caregiver’s perception of the patient’s behavior [61]. The significant placebo response we observed on subjective outcomes (evaluation of the patient by a third person) are likely related to the latter. Grelotti and Kaptchuk argue that "if clinicians and family members feel empowered and optimistic about a treatment, they may smile more, pay more attention to the patient, promote treatment adherence, encourage the patient to engage in new activities etc" [60]. In this way, Grelotti and Kaptchuk suggest that placebo by proxy changes the patient’s psychosocial context, and mediates the placebo effect in a way that is not strictly a learning phenomenon or conscious expectancy; yet it may have the same profound influence on patient’s physiology. Placebo by proxy has also been observed in children with tantrums [61], autism [62], cerebral palsy and Attention-Deficit/Hyperactivity Disorder (ADHD) [63] and it is likely that this mechanism play a major role in ID trials, as ID patients are very sensitive to changes in their environment [64–66]. In the case of placebo by proxy, it is the treatment expectations of the clinicians and family members that elicit a placebo effect on the ID patient mediated by altered behavior toward him.

Contrary to our findings, a previous study speculated that ID patients would not display placebo responses, as there is evidence for loss of placebo responses in patients with dementia (due to impaired cognitive functioning) [67]. This furthers the notion that patients with genetically determined ID may have developed an alternate mechanism for placebo responses that relies on an early compensatory adaption. As ID patients are born with cognitive impairments, it is likely that adaptive responses to the challenges in the environment occur with time. In dementia however, already established response patterns are disrupted, leaving the patient with
severe cognitive disabilities. Along these lines, the placebo responses in ID patients could be described as a “low road” adaptation, which is not related to higher-order cognitive function (possibly through patients’ enhanced sensitivity to contextual and social cues), compared to the “high road” predictions and expectations described in healthy individuals.

IQ

Even if patients with ID display robust overall placebo responses, there was a significant effect of IQ on placebo effect size (but not on drug effect size). It is possible that high-functioning ID patients have a normal placebo response, but at a certain degree of intellectual impairment there is no longer a response. Since a limited number of clinical trials reported IQ levels for their patients, our findings should be confirmed in future analysis where the relationship between IQ and placebo responses can be further explored. We found that ID patients displayed significant placebo responses before, but not after, onset of dementia, confirming the previous mentioned study suggesting decreased placebo responses related to severe loss of cognitive skills in patients with dementia [67].

Trial duration

Placebo effects are anecdotally thought to have a short duration, as they rely on learning mechanisms that may wane with time [49]. Here, we found that the placebo responses were stable over time, in spite of trials lasting up to three years. This is in line with the stable placebo effects seen in various long lasting clinical trials [68, 69]. We hope that future studies will investigate the long-term effects of placebo treatment in ID patients.

Syndrome-related specificities

We found placebo responses both in DS and FX patients, but cannot conclude anything about PW given the small number of studies. DS and FX patients both exhibit a moderate to severe range of ID but have different social and affective profiles. DS patients are frequently reported to demonstrate empathy and care for others, showing concern and offering comfort to the person in distress [70], while FX patients display social hyper-arousal, which leads to gaze aversion, social difficulties and anxiety [71, 72]. In both syndromes, ID patients usually would like to please their doctor and caretaker [73]. Both DS and FX patients are sensitive to surrounding cues of expectancy, even if it may be from different disorder-specific abilities (e.g. good social and communicative skills in DS; and lack of inhibition or filtering of the environment in FX) [74–77].

Age

We found a significant relationship between age and placebo effect size, with higher placebo responses in very young children. Four trials included children at birth and it is likely that the high placebo response is an effect of a particularly intensive placebo by proxy in newborns. A recent review suggests an inverse relationship between age and placebo effect size in healthy children [50], validating our findings in patients with ID. Children tend to assume that they are receiving real medication more often than adults [78] and meta-analyses across several medical disciplines report robust placebo responses in children [50, 79–81].

Placebo in different cognitive and behavioral domains

The placebo effect differed significantly by mental process categories. Even if this could partly be an effect of the different scale sensitivities, it is possible that placebo responses are not
equally expressed across domains. Many different scales were used in the different clinical trials included here. Future work is necessary (as suggested by the recent meeting convened by the National Institutes of Health, Washington DC, 2012) in order to identify reliable and sensitive outcome measures for common use in clinical trials in FX [82] and more generally in ID patients.

Limitations and future perspectives

As previously mentioned, there is always a possibility that the placebo response is partially represented by spontaneous remission, or the natural history of the condition being treated. However, this study only includes patients with genetically determined ID, which is a condition without spontaneous remission [2]. Nevertheless, even if the intellectual disability will not improve over time, some comorbid symptoms may fluctuate over time, such as tantrums, hyperactivity or agitation [73]. As some of them may be included as outcome measures to evaluate the behavior of the patients, it is likely that these outcomes may be more sensitive to placebo too. If future pharmacological trials include a natural history control arm, in addition to the traditional placebo control arm, there can be a better estimation of the possible contributions of bias to the placebo response.

No significant drug versus placebo effect was observed in our meta-analysis. Yet, novel and hopefully more efficient treatment options for ID are beginning to appear for a number of specific conditions, such as DS and FX [3]. These pathophysiologically targeted treatments are focusing on correcting the underlying defect, via re-equilibration of the biochemical imbalance that results from genetic mutations, instead of suppressing only some of the most pervasive symptoms [83]. Some preliminary results have been promising [84] and raised the expectancy in patient’s families. Given the recent example of secretin trials in children with autism [62, 63], showing robust and consistent reductions in symptoms, but no difference between secretin over placebo, it is necessary to be vigilant on the role of placebos when testing novel treatments in ID.

Supporting Information

S1 File. PRISMA 2009 checklist.

(DOCX)

Author Contributions

Conceived and designed the experiments: AC IK TJK KBJ. Performed the experiments: AC KY KBJ. Analyzed the data: AC KY IK KBJ. Contributed reagents/materials/analysis tools: AC KY IK TJK KBJ. Wrote the paper: AC KY IK RLG VDP TJK KBJ. Interpretation of the data: AC KY IK RLG VDP TJK KBJ.

References

1. Association AP. Diagnostic and statistical manual of mental disorders: DSM-5 (5th ed.). Arlington, VA: American Psychiatric Publishing, Inc 2013.
2. Teipel SJ, Hampel H. Neuroanatomy of Down syndrome in vivo: a model of preclinical Alzheimer’s disease. Behav Genet. 2006; 36(3):405–15. doi: 10.1007/s10519-006-9047-x PMID: 16485178.
3. Picker JD, Walsh CA. New innovations: therapeutic opportunities for intellectual disabilities. Ann Neurol. 2013; 74(3):382–90. doi: 10.1002/ana.24002 PMID: 24038210; PubMed Central PMCID: PMC3876407.
4. Buchel C, Geuter S, Sprenger C, Eippert F. Placebo analgesia: a predictive coding perspective. Neuron. 2014; 81(6):1223–39. doi: 10.1016/j.neuron.2014.02.042 PMID: 24656247.
5. Waber RL, Shiv B, Camron Z, Ariely D. Commercial features of placebo and therapeutic efficacy. JAMA. 2008; 299(9):1016–7. doi: 10.1001/jama.299.9.1016 PMID: 18319411.
6. Kaptchuk TJ, Kelley JM, Conboy LA, Davis RB, Kerr CE, Jacobson EE, et al. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ. 2008; 336(7651):999–1003. doi: 10.1136/bmj.39524.439618.25 PMID: 18390493

7. Colloca L, Sigaudo M, Benedetti F. The role of learning in nocebo and placebo effects. Pain. 2008; 136(1–2):211–20. doi: 10.1016/j.pain.2008.02.006 PMID: 18372113.

8. Allan LG, Siegel S. A signal detection theory analysis of the placebo effect. Eval Health Prof. 2002; 25(4):410–20. PMID: 12449084.

9. Enck P, Bingel U, Schedlowski M, Rief W. The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov. 2013; 12(3):191–204. doi: 10.1038/nrd3923 PMID: 23449306.

10. de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ. Expectation and dopamine release: mechanism of the placebo effect in Parkinson’s disease. Science. 2001; 293(5532):1164–6. doi: 10.1126/science.1060937 PMID: 11498597.

11. Benedetti F, Colloca L, Torre E, Lanotte M, Melcarne A, Pesare M, et al. Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus. Nat Neurosci. 2004; 7(6):587–8. doi: 10.1038/nn1250 PMID: 15146189.

12. Eippert F, Bingel U, Schoell ED, Yacubian J, Klinger R, Lorenz J, et al. Activation of the opioidergic descending pain control system underlies placebo analgesia. Neurog. 2009; 63(4):533–43. doi: 10.1016/j.neuron.2009.07.014 PMID: 19709634.

13. Petrovic P, Kalso E, Petersson KM, Ingvar M. Placebo and opioid analgesia—imaging a shared neural network. Science. 2002; 295(5560):1737–40. doi: 10.1126/science.1067176 PMID: 11834781.

14. Wager TD, Rilling JK, Smith EE, Sokolik A, Casey KL, Davidson RJ, et al. Placebo-Induced Changes in fMRI in the Anticipation and Experience of Pain. Science. 2004; 303(5661):1162–7. doi: 10.1126/science.1093065 PMID: 14976306.

15. Zubieta JK, Bueller JA, Jackson LR, Schoell E, Weiller C, Buchel C. Direct Evidence for Spinal Cord Involvement in Placebo Analgesia. Science. 2002; 26(2):559–63. doi: 10.1126/science.1060937 PMID: 11498597.

16. Leuchter AF, Cook IA, Witte EA, Morgan M, Abrams M. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry. 2002; 159(1):122–9. PMID: 11772700.

17. Furmark T, Appel L, Henningsson S, Ahs F, Faria V, Linman C, et al. A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety. J Neurosci. 2008; 28(49):13066–74. doi: 10.1523/JNEUROSCI.2534-08.2008 PMID: 19052197.

18. Petrovic P, Dietrich T, Fransson P, Andersson J, Carlsson J, Ingvar M. Placebo in emotional processing—induced expectations of anxiety relief activate a generalized modulatory network. Neuron. 2005; 46(6):957–69. doi: 10.1016/j.neuron.2005.05.023 PMID: 15953423.

19. Bingel U, Lorenz J, Schoell E, Weiller C, Buchel C. Mechanisms of placebo analgesia: rACC recruitment of a subcortical antinociceptive network. Pain. 2006; 120(1–2):B–8. doi: 10.1016/j.pain.2005.08.027 PMID: 16364549.

20. Eippert F, Finsterbusch J, Bingel U, Buchel C. Direct Evidence for Spinal Cord Involvement in Placebo Analgesia. Science. 2009; 326(5951):404–9. doi: 10.1126/science.1180142 PMID: 19833962.

21. Matre D, Casey KL, Knardahl S. Placebo-induced changes in spinal cord pain processing. J Neurosci. 2006; 26(2):559–63. doi: 10.1523/JNEUROSCI.4128-05.2006 PMID: 16407554.

22. Jensen KB, Kaptchuk TJ, Kirsch I, Raicek J, Lindstrom KM, Berna C, et al. Nonconscious activation of placebo and nocebo pain responses. Proc Natl Acad Sci U S A. 2012; 109(39):15959–64. doi: 10.1073/pnas.1202056109 PMID: 23019380; PubMed Central PMCID: PMC3465419.

23. Jensen KB, Kaptchuk TJ, Chen X, Kirsch I, Ingvar M, Gollub RL, et al. A Neural Mechanism for Nonconscious Activation of Conditioned Placebo and Nocebo Responses. Cereb Cortex. 2014. doi:10.1093/cercor/bhu275 PMID: 24522549.

24. Brockwell SE, Gordon IR. A comparison of statistical methods for meta-analysis. Stat Med. 2001; 20(6):825–40. doi: 10.1002/sim.650 PMID: 11252006.

25. Bennett FC, McClelland S, Kriegsmann EA, Andrus LB, Sells CJ. Vitamin and mineral supplementation in Down’s syndrome. Pediatrics. 1983; 72(5):707–13. PMID: 6226926.

26. Berry-Kravis E, Krause SE, Block SS, Guter S, Wuu J, Leurgans S, et al. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol. 2006; 16(5):525–40. doi: 10.1089/cap.2006.16.525 PMID: 17069542.

27. Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Brown K, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med. 2012; 4(152):152ra27. doi: 10.1126/scitranslmed.3004214 PMID: 22993294.
28. Blehaut H, Mircher C, Ravel A, Conte M, de Portzamparc V, Poret G, et al. Effect of leucovorin (folinic acid) on the developmental quotient of children with Down's syndrome (trisomy 21) and influence of thyroid status. PLoS One. 2010; 5(1):e8394. doi: 10.1371/journal.pone.0008394 PMID: 20084109; PubMed Central PMCID: PMC2799517.

29. Boada R, Hutaff-Lee C, Schrader A, Weitenkamp D, Benke TA, Goldson EJ, et al. Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial. Transl Psychiatry. 2012; 2:e141. doi: 10.1038/tj.2012.66 PMID: 22806212; PubMed Central PMCID: PMC3410988.

30. Ellis JM, Tan HK, Gilbert RE, Muller DP, Henley W, Moy R, et al. Supplementation with antioxidants and folic acid for children with Down's syndrome: randomised controlled trial. BMJ. 2008; 336(7644):594–7. doi: 10.1136/bmj.39465.544028.AE PMID: 18296460; PubMed Central PMCID: PMC2267986.

31. Hagerman RJ, Jackson AW, Levitas A, Braden M, McBogg P, Kemper M, et al. Oral folic acid versus placebo in the treatment of males with the fragile X syndrome. Am J Med Genet. 1986; 23(1–2):241–62. PMID: 3513567.

32. Hanney M, Prasher V, Williams N, Jones EL, Aarsland D, Corbett A, et al. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet. 2012; 379(9815):528–36. doi: 10.1016/S0140-6736(11)61876-0 PMID: 22236802.

33. Haqq AM, Stadler DD, Jackson RH, Rosenfeld RG, Purnell JQ, LaFranchi SH. Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome. J Clin Endocrinol Metab. 2003; 88(5):2206–12. doi: 10.1210/jc.2002-012513 PMID: 12727976.

34. Johnson N, Fahey C, Chicoine B, Chong G, Gitelman D. Effects of donepezil on cognitive functioning in Down syndrome. Am J Ment Retard. 2003; 108(6):367–72. doi: 10.1352/0895-8017(2003)108<367:EFoDG>2.0.CO;2 PMID: 14561111.

35. Kishnani PS, Sommer BR, Handen BL, Seltzer B, Capone GT, Spiridigliozzi GA, et al. The efficacy, safety, and tolerability of donepezil for the treatment of young adults with Down syndrome. Am J Med Genet A. 2009; 149A(8):164–54. doi: 10.1002/ajmg.a.32953 PMID: 19606472.

36. Kishnani PS, Heller JH, Spiridigliozzi GA, Lott I, Escobar L, Richardson S, et al. Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10–17. Am J Med Genet A. 2010; 152A(12):3028–35. doi: 10.1002/ajmg.a.33730 PMID: 21108390.

37. Kondoh T, Kanno A, Itoh H, Nakashima M, Honda R, Kojima M, et al. Donepezil significantly improves abilities in daily lives of female Down syndrome patients with severe cognitive impairment: a 24-week randomized, double-blind, placebo-controlled trial. Int J Psychiatry Med. 2011; 41(1):71–89. PMID: 21495523.

38. Leigh MJ, Nguyen DV, Mu Y, Winarni TI, Schneider A, Chechi T, et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome. J Dev Behav Pediatr. 2013; 34(3):147–55. doi: 10.1097/DBP.0b013e3182827cd17 PMID: 23572165; PubMed Central PMCID: PMC3706260.

39. Prasher VP, Huxley A, Haque MS, Down syndrome Ageing Study G. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease—pilot study. Int J Geriatr Psychiatry. 2002; 17(3):270–8. PMID: 11921156.

40. Pueschel SM, Reed RB, Cronk CE, Goldstein BJ. 5-hydroxytryptophan and pyridoxine. Their effects in young children with Down's syndrome. Am J Dis Child. 1980; 134(9):838–44. PMID: 6447999.

41. Sahu JK, Gulati S, Sapra S, Arya R, Chauhan S, Chowdhury MR, et al. Effectiveness and safety of donepezil in boys with fragile x syndrome: a double-blind, randomized, controlled pilot study. J Child Neurol. 2013; 28(5):570–5. doi: 10.1177/0883073812449381 PMID: 22752489.

42. Selikowitz M, Sunman J, Pendergast A, Wright S, Fenfluramine in Prader-Willi syndrome: a double blind, placebo controlled trial. Arch Dis Child. 1990; 65(1):112–4. PMID: 2405783; PubMed Central PMCID: PMC1799517.

43. Smith GF, Spiker D, Peterson CP, Cicchetti D, Justine P. Use of megadoses of vitamins with minerals in Down syndrome. J Pediatr. 1984; 105(2):228–34. PMID: 6235336.

44. Torrioli MG, Vernacotola S, Peruzzi L, Tabolacci E, Mila M, Milletini R, et al. A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet A. 2008; 146A(7):803–12. doi: 10.1002/ajmg.a.32268 PMID: 18286595.

45. van Trotsenburg AS, Vulsma T, van Rozenburg-Mares SL, van Baar AL, Ridder JC, Heymans HS, et al. The effect of thyroxine treatment started in the neonatal period on growth and development of
two-year-old Down syndrome children: a randomized clinical trial. J Clin Endocrinol Metab. 2005; 90 (6):3304–11. doi: 10.1210/jc.2005-0130 PMID: 15755847.

46. Weathers C. Effects of nutritional supplementation on IQ and certain other variables associated with Down syndrome. Am J Ment Defic. 1983; 88(2):214–7. PMID: 6227244.

47. Sauro MD, Greenberg RP. Endogenous opiates and the placebo effect: a meta-analytic review. J Psychosom Res. 2005; 58(2):115–20. doi: 10.1016/j.jpsychores.2004.07.001 PMID: 15820838.

48. Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis. 2008; 67(12):1716–23. doi: 10.1136/ard.2008.092015 PMID: 18541604.

49. Walach HaM, C. Is the placebo effect dependent on time? A meta-analysis. in Kirsch I, editor. Washington, D.C.: American Psychological Association; 1999. 321–32 p.

50. Weimer K, Gulewitsch MD, Schlarb AA, Schwille-Kiuntke S, Enck P. Placebo effects in children: a review. Pediatr Res. 2013; 74(1):96–102. doi: 10.1038/pr.2009.01.029 PMID: 19246102.

51. Rief W, Nestoriuc Y, Weiss S, Welzel E, Barsky AJ, Hofmann SG. Meta-analysis of the placebo response in antidepressant trials. J Affect Disord. 2009; 118(1–3):1–8. doi: 10.1016/j.jad.2009.01.029 PMID: 19246102.

52. Patelm SM, Stason WB, Legedza A, Ock SM, Kaptchuk TJ, Conboy L, et al. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil. 2005; 17(3):332–40. doi: 10.1111/j.1365-2982.2005.00650.x PMID: 15916620.

53. Fulda S, Wetter TC. Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies. Brain. 2008; 131(Pt 4):902–17. doi: 10.1093/brain/awm244 PMID: 17932100.

54. Rutherford BR, Pott E, Tandler JM, Wall MM, Roose SP, Lieberman JA. Placebo response in antipsychotic clinical trials: a meta-analysis. JAMA Psychiatry. 2014; 71(12):1409–21. doi: 10.1001/jamapsychiatry.2014.1319 PMID: 25321611; PubMed Central PMCID: PMC4256120.

55. Finniss DG, Kaptchuk TJ, Miller F, Benedetti F. Biological, clinical, and ethical advances of placebo effects. Lancet. 2010; 375(9715):686–95. doi: 10.1016/S0140-6736(09)61706-2 PMID: 20171404; PubMed Central PMCID: PMC2832199.

56. Price DD, Finniss DG, Benedetti F. A comprehensive review of the placebo effect: recent advances and current thought. Annu Rev Psychol. 2008; 59:565–90. doi: 10.1146/annurev.psych.59.113006.095941 PMID: 17550344.

57. Klinger R, Soost S, Flor H, Worm M. Classical conditioning and expectancy in placebo hypoalgesia: a randomized controlled study in patients with atopic dermatitis and persons with healthy skin. Pain. 2007; 128(1–2):31–9. doi: 10.1016/j.pain.2006.08.025 PMID: 17030095.

58. Talbot WA, Pinchbeck GL, Knottenbelt DC, Graham H, McKane SA. A randomised, blinded, crossover study to assess the efficacy of a feed supplement in alleviating the clinical signs of headshaking in 32 horses. Equine Vet J. 2013; 45(3):293–7. doi: 10.1111/j.2042-3306.2012.00618.x PMID: 22994634.

59. Grelotti DJ, Kaptchuk TJ. Placebo by proxy. BMJ. 2011; 343:d4345. doi: 10.1136/bmj.d4345 PMID: 21833868; PubMed Central PMCID: PMC3230083.

60. Whalley B, Hyland ME. Placebo by proxy: the effect of parents' beliefs on therapy for children's temper tantrums. J Behav Med. 2013; 36(4):341–6. doi: 10.1007/s10865-012-9429-x PMID: 22580966.

61. Sandler AD, Bodfish JW. Placebo effects in autism: lessons from secretin. J Dev Behav Pediatr. 2000; 21(5):347–50. PMID: 11064962.

62. Williams KW, Wray JJ, Wheeler DM. Intravenous secretin for autism spectrum disorder. Cochrane Database Syst Rev. 2005;(3):CD003495. doi: 10.1002/14651858.CD003495.pub2 PMID: 16034901.

63. Hessl D, Berry-Kravis E, Cordeiro L, Yuhas J, Omitz EM, Campbell A, et al. Prepulse inhibition in fragile X syndrome: feasibility, reliability, and implications for treatment. Am J Med Genet B Neuropsychiatr Genet. 2009; 150B(4):545–53. doi: 10.1002/ajmg.b.30858 PMID: 18785205; PubMed Central PMCID: PMC2693303.
67. Benedetti F, Arduino C, Costa S, Vighetti S, Tarenzi L, Rainero I, et al. Loss of expectation-related mechanisms in Alzheimer's disease makes analgesic therapies less effective. Pain. 2006; 121(1-2):133–44. doi: 10.1016/j.pain.2005.12.016 PMID: 16473462.

68. Khan A, Redding N, Brown WA. The persistence of the placebo response in antidepressant clinical trials. J Psychiatr Res. 2008; 42(10):791–6. doi: 10.1016/j.jpsychires.2007.10.004 PMID: 18036616.

69. Rana JS, Mannam A, Donnell-Fink L, Gervino EV, Sellke FW, Laham RJ. Longevity of the placebo effect in the therapeutic angiogenesis and laser myocardial revascularization trials in patients with coronary heart disease. Am J Cardiol. 2005; 95(12):1456–9. doi: 10.1016/j.amjcard.2005.02.013 PMID: 15950570.

70. Kasari C, Freeman SF, Bass W. Empathy and response to distress in children with Down syndrome. J Child Psychol Psychiatry. 2003; 44(3):424–31. PMID: 12635971.

71. Hagerman RJ, Hagerman PJ. The fragile X premutation: into the phenotypic fold. Curr Opin Genet Dev. 2002; 12(3):278–83. PMID: 12076670.

72. Lightbody AA, Reiss AL. Gene, brain, and behavior relationships in fragile X syndrome: evidence from neuroimaging studies. Dev Disabil Res Rev. 2009; 15(4):343–52. doi: 10.1002/ddrr.77 PMID: 20014368; PubMed Central PMCID: PMC4354896.

73. Greico J, Pulsifer M, Seligsohn K, Skotko B, Schwartz A. Down syndrome: Cognitive and behavioral functioning across the lifespan. Am J Med Genet C Semin Med Genet. 2015; 169(2):135–49. doi: 10.1002/ajmg.c.31439 PMID: 25989505.

74. Finestack LH, Richmond EK, Abbeduto L. Language Development in Individuals with Fragile X Syndrome. Top Lang Disord. 2009; 29(2):133–48. PMID: 20396595; PubMed Central PMCID: PMC2854517.

75. Hooper SR, Hatton D, Sideris J, Sullivan K, Hammer J, Schaaf J, et al. Executive functions in young males with fragile X syndrome in comparison to mental age-matched controls: baseline findings from a longitudinal study. Neuropsychology. 2008; 22(1):36–47. doi: 10.1037/0894-4105.22.1.36 PMID: 18211154.

76. Lott IT, Dierssen M. Cognitive deficits and associated neurological complications in individuals with Down's syndrome. Lancet Neurol. 2010; 9(6):623–33. doi: 10.1016/S1474-4422(10)70112-5 PMID: 20494326.

77. Vicari S, Pontillo M, Armando M. Neurodevelopmental and psychiatric issues in Down's syndrome: assessment and intervention. Psychiatr Genet. 2013; 23(3):95–107. doi: 10.1097/YPG.0b013e2825fe426 PMID: 23492931.

78. Rothner AD, Wasiwaski W, Winner P, Lewis D, Stankowski J. Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents. Headache. 2006; 46(1):101–9. doi: 10.1111/j.1526-4610.2006.00313.x PMID: 16412157.

79. Faria V, Linnman C, Lebel A, Borsook D. Harnessing the placebo effect in pediatric migraine clinic. J Pediatr. 2014; 165(4):659–65. doi: 10.1016/j.jpeds.2014.06.040 PMID: 25063720; PubMed Central PMCID: PMC4358740.

80. El-Chammas K, Keyes J, Thompson N, Vijayakumar J, Becher D, Jackson JL. Pharmacologic treatment of pediatric headaches: a meta-analysis. JAMA Pediatr. 2013; 167(3):250–8. doi: 10.1001/jamapediatrics.2013.508 PMID: 23589335.

81. Rheims S, Cucherat M, Arzimanoglou A, Ryvlin P. Greater response to placebo in children than in adults: a systematic review and meta-analysis in drug-resistant partial epilepsy. PLoS Med. 2008; 5(8):e166. doi: 10.1371/journal.pmed.0050166 PMID: 18700812; PubMed Central PMCID: PMC2504483.

82. Berry-Kravis E, Hessl D, Abbeduto L, Reiss AL, Beckel-Mitchener A, Urv TK, et al. Outcome measures for clinical trials in fragile X syndrome. J Dev Behav Pediatr. 2013; 34(7):508–22. doi: 10.1097/DBP.0b013e31829d1120 PMID: 24042082; PubMed Central PMCID: PMC3784007.

83. Hagerman R, Lauterborn J, Au J, Berry-Kravis E. Fragile X syndrome and targeted treatment trials. Results Probl Cell Differ. 2012; 54:297–335. doi: 10.1007/978-3-642-21649-7_17 PMID: 2209360; PubMed Central PMCID: PMC4114775.

84. Jacquemont S, Curie A, de Portes V, Torrioli MG, Berry-Kravis E, Hagerman RJ, et al. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med. 2011; 3(64):64ra1. doi: 10.1126/scitranslmed.3001708 PMID: 21209411.